DNA methylome alterations in chemical carcinogenesis

Cancer Letters

Volumn 334, Issue 1, 2013, Pages 39-45

  Pogribny, Igor P ^a   Beland, Frederick A ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Carcinogenesis; DNA methylation; Genotoxic carcinogens; Non genotoxic carcinogens

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; CARCINOGEN; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; GENOMIC DNA; MUTAGENIC AGENT;

CANCER GENETICS; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; COLORECTAL CANCER; CPG ISLAND; DEMETHYLATION; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENETIC RISK; HUMAN; LEUKEMOGENESIS; LIVER CARCINOGENESIS; LUNG CARCINOGENESIS; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RISK ASSESSMENT; SHORT SURVEY; SMOKING; CHEMICALLY INDUCED; COLORECTAL TUMOR; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; LEUKEMIA; LIVER TUMOR; LUNG TUMOR; METABOLISM; NEOPLASM; PROCEDURES;

CARCINOGENS; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA; LIVER NEOPLASMS; LUNG NEOPLASMS; MUTAGENS; NEOPLASMS; RISK ASSESSMENT;

EID: 84891938029     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.010     Document Type: Review

References (141)

1. Wild C.P. Environmental exposure measurement in cancer epidemiology. Mutagenesis 2009, 24:117-125.
2. Clapp R.W., Jacobs M.M., Loechler E.L. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev. Environ. Health 2008, 23:1-37.
3. Rappaport S.M. Discovering environmental causes of disease. J. Epidemiol. Commun. Health 2012, 66:99-102.
4. Miller J.A. Carcinogenesis by chemicals: an overview - G.H.A. Clowes memorial lecture. Cancer Res. 1970, 30:559-576.
5. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007, 22:91-103.
6. Pogribny I.P., Rusyn I., Beland F.A. Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents. Environ. Mol. Mutagen. 2008, 49:9-15.
7. Nakajima T., Enomoto S., Ushijima T. DNA methylation: a marker for carcinogen exposure and cancer risk. Environ. Health Prev. Med. 2008, 13:8-15.
8. D. Ziech, R. Franco, A. Pappa, V. Malamou-Mitsi, S. Georgakila, A.G. Georgakilas, M.I. Panayiotidis, The role of epigenetics in environmental and occupational carcinogenesis, Chem.-Biol. Interact. 188 (2010) 340-349.
9. Hou L., Zhang X., Wang D., Baccarelli A. Environmental chemical exposures and human epigenetics. Int. J. Epidemiol. 2012, 41:79-105.
10. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., Nery J.R., Lee L., Ye Z., Ngo Q.-M., Edsall L., Antosiewicz-Bourget J., Stewart R., Ruotti V., Millar A.H., Thomson J.A., Ren B., Ecker J.R. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
11. Liang G., Chan M.F., Tomigahara Y., Tsai Y.C., Gonzales F.A., Li E., Laird P.W., Jones P.A. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell. Biol. 2002, 22:480-491.
12. Ooi S.K.T., O'Donnell A.H., Bestor T.H. Mammalian cytosine methylation at a glance. J. Cell Sci. 2009, 22:2787-2791.
13. Denis H., Ndlovu M.N., Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep. 2011, 12:647-656.
14. Rollins R.A., Haghighi F., Edwards J.R., Das R., Zhang M.Q., Ju J., Bestor T.H. Large-scale structure of genomic methylation patterns. Genome Res. 2006, 16:157-163.
15. Takai D., Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA 2002, 99:3740-3745.
16. Illingworth R.S., Bird A.P. CpG islands - 'Arough guide'. FEBS Lett. 2009, 583:1713-1720.
17. Maunakea A.K., Nagarajan R.P., Bilenky M., Ballinger T.J., D'Souza C., Fouse S.D., Johnson B.E., Hong C., Nielsen C., Zhao Y., Turecki G., Delaney A., Varhol R., Thiessen N., Shchors K., Heine V.M., Rowitch D.H., Xing X., Fiore C., Schillebeeckx M., Jones S.J.M., Haussler D., Marra M.A., Hirst M., Wang T., Costello J.F. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466:253-257.
18. Pogribny I.P., Beland F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell. Mol. Life Sci. 2009, 66:2249-2261.
19. Gehring M., Reik W., Henikoff S. DNA demethylation by DNA repair. Trends Genet. 2009, 25:82-90.
20. Ma D.K., Guo J.U., Ming G.-l., Song H. DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. Cell Cycle 2009, 8:1526-1531.
21. He Y.-F., Li B.-Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., Sun Y., Li X., Dai Q., Song C.-X., Zhang K., He C., Xu G.-L. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
22. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
23. Chen R.Z., Pettersson U., Beard C., Jackson-Grusby L., Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395:89-93.
24. Rodriguez J., Frigola J., Vendrell E., Risques R.-A., Fraga M.F., Morales C., Moreno V., Esteller M., Capellà G., Ribas M., Peinado M.A. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 2006, 66:8462-8468.
25. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002, 21:5400-5413.
26. Feinberg A.P., Cui H., Ohlsson R. DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin. Cancer Biol. 2002, 12:389-398.
27. Uribe-Lewis S., Woodfine K., Stojic L., Murrell A. Molecular mechanisms of genomic imprinting and clinical implications for cancer. Expert Rev. Mol. Med. 2011, 13:e2.
28. Jelinic P., Shaw P. Loss of imprinting and cancer. J. Pathol. 2007, 211:261-268.
29. Cui H., Onyango P., Brandenburg S., Wu Y., Hsieh C.-L., Feinberg A.P. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002, 62:6442-6446.
30. KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J. Med. Genet. 2003, 40:797-801.
31. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
32. Wong N.C., Wong L.H., Quach J.M., Canham P., Craig J.M., Song J.Z., Clark S.J., Choo K.H.A. Permissive transcriptional activity at the centromere through pockets of DNA hypomethylation. PLoS Genet. 2006, 2:e17.
33. Howard G., Eiges R., Gaudet F., Jaenisch R., Eden A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2008, 27:404-408.
34. Vera E., Canela A., Fraga M.F., Esteller M., Blasco M.A. Epigenetic regulation of telomeres in human cancer. Oncogene 2008, 27:6817-6833.
35. Münzel M., Globisch D., Carell T. 5-Hydroxymethylcytosine, the sixth base of the genome. Angew. Chem. Int. Ed. 2011, 50:6460-6468.
36. Song C.-X., He C. The hunt for 5-hydroxymethylcytosine: the sixth base. Epigenomics 2011, 3:521-523.
37. Jin S.-G., Jiang Y., Qiu R., Rauch T.A., Wang Y., Schackert G., Krex D., Lu Q., Pfeifer G.P. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011, 71:7360-7365.
38. Kudo Y., Tateishi K., Yamamoto K., Yamamoto S., Asaoka Y., Ijichi H., Nagae G., Yoshida H., Aburatani H., Koike K. Loss of 5-hydroxymethylcytosine is accompanied with malignant cell transformation. Cancer Sci. 2012, 103:670-676.
39. H. Yang, Y. Liu, F. Bai, J.-Y. Zhang, S.-H. Ma, J. Liu, Z.-D. Xu, H.-G. Zhu, Z.-Q. Ling, D. Ye, K.-L. Guan, Y. Xiong, Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation, Oncogene, in press.
40. Kraus T.F.J., Globisch D., Wagner M., Eigenbrod S., Widmann D., Münzel M., Müller M., Pfaffeneder T., Hackner B., Feiden W., Schüller U., Carell T., Kretzschmar H.A. Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base", are associated with anaplasia in human brain tumors. Int. J. Cancer 2012, 131:1577-1590.
41. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
42. Deaton A.M., Bird A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25:1010-1022.
43. Chuang J.C., Jones P.A. Epigenetics and microRNAs. Pediatr. Res. 2007, 61:24R-29R.
44. Lujambio A., Portela A., Liz J., Melo S.A., Rossi S., Spizzo R., Croce C.M., Calin G.A., Esteller M. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 2010, 29:6390-6401.
45. Jacinto F.V., Esteller M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007, 22:247-253.
46. Lahtz C., Pfeifer G.P. Epigenetic changes of DNA repair genes in cancer. J. Mol. Cell Biol. 2011, 3:51-58.
47. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000, 60:2368-2371.
48. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001, 61:4689-4692.
49. Birgisdottir V., Stefansson O.A., Bodvarsdottir S.K., Hilmarsdottir H., Jonasson J.G., Eyfjord J.E. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006, 8:R38.
50. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.-P.J., Markowitz S., Willson J.K.V., Hamilton S.R., Kinzler K.W., Kane M.F., Kolodner R.D., Vogelstein B., Kunkel T.A., Baylin S.B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA 1998, 95:6870-6875.
51. Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., Ji H., Potash J.B., Sabunciyan S., Feinberg A.P. The human colon methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41:178-186.
52. Pogribny I.P., James S.J. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Lett. 2002, 176:169-174.
53. Han H., Cortez C.C., Yang X., Nichols P.W., Jones P.A., Liang G. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum. Mol. Genet. 2011, 20:4299-4310.
54. Shenker N., Flanagan J.M. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br. J. Cancer 2012, 106:248-253.
55. Tomasi M.L., Li T.W.H., Li M., Mato J.M., Lu S.C. Inhibition of human methionine adenosyltransferase 1A transcription by coding region methylation. J. Cell. Physiol. 2012, 227:1583-1591.
56. Shen L., Kondo Y., Guo Y., Zhang J., Zhang L., Ahmed S., Shu J., Chen X., Waterland R.A., Issa J.-P.J. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 2007, 3:2023-2036.
57. Fernandez A.F., Assenov Y., Martin-Subero J.I., Balint B., Siebert R., Taniguchi H., Yamamoto H., Hidalgo M., Tan A.-C., Galm O., Ferrer I., Sanchez-Cespedes M., Villanueva A., Carmona J., Sanchez-Mut J.V., Berdasco M., Moreno V., Capella G., Monk D., Ballestar E., Ropero S., Martinez R., Sanchez-Carbayo M., Prosper F., Agirre X., Fraga M.F., Graña O., Perez-Jurado L., Mora J., Puig S., Prat J., Badimon L., Puca A.A., Meltzer S.J., Lengauer T., Bridgewater J., Bock C., Esteller M. A DNA methylation fingerprint of 1628 human samples. Genome Res. 2012, 22:407-419.
58. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
59. Robertson K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20:3139-3155.
60. Szyf M., Detich N. Regulation of the DNA methylation machinery and its role in cellular transformation. Prog. Nucl. Acid Res. Mol. Biol. 2001, 69:47-79.
61. El-Osta A. DNMT cooperativity - the developing links between methylation, chromatin structure and cancer. BioEssays 2003, 25:1071-1084.
62. Daniel F.I., Cherubini K., Soares Yurgel L., Zancanaro de Figueiredo M.A., Gonçalves Salum F. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011, 117:677-687.
63. Berger J., Bird A. Role of MBD2 in gene regulation and tumorigenesis. Biochem. Soc. Trans. 2005, 33:1537-1540.
64. Ballestar E., Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem. Cell Biol. 2005, 83:374-384.
65. Teodoridis J.M., Hardie C., Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett. 2008, 268:177-186.
66. Daskalos A., Oleksiewicz U., Filia A., Nikolaidis G., Xinarianos G., Gosney J.R., Malliri A., Field J.K., Liloglou T. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer 2011, 117:1027-1037.
67. Bacher U., Haferlach C., Schnittger S., Kohlmann A., Kern W., Haferlach T. Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann. Hematol. 2010, 89:643-652.
68. Williams K., Christensen J., Helin K. DNA methylation: TET proteins - guardians of CpG islands?. EMBO Rep. 2012, 13:28-35.
69. Pronier E., Delhommeau F. Role of TET2 mutations in myeloproliferative neoplasms. Curr. Hematol. Malig. Rep. 2012, 7:57-64.
70. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. J. Thorac. Oncol. 2008, 3:819-831.
71. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
72. IARC Monographs on the Evaluations of Carcinogenic Risks to Humans, vol. 83, Tobacco Smoke and Involuntary Smoking, IARC, Lyon, France, 2004, pp. 1-1452.
73. IARC Monographs on the Evaluations of Carcinogenic Risks to Humans, vol. 100, A Review of Human Carcinogens, Part E: Personal Habits and Indoor Combustions, IARC, Lyon, France, 2012, pp. 1-579.
74. Walser T., Cui X., Yanagawa J., Lee J.M., Heinrich E., Lee G., Sharma S., Dubinett S.M. Smoking and lung cancer: The role of inflammation. Proc. Am. Thorac. Soc. 2008, 5:811-815.
75. Hecht S.S. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch. Surg. 2006, 391:603-613.
76. De Matteis S., Consonni D., Bertazzi P.A. Exposure to occupational carcinogens and lung cancer risk. Evolution of epidemiological estimates of attributable fraction. Acta Biomed. 2008, 79(Suppl. 1):34-42.
77. Olsson A.C., Fevotte J., Fletcher T., Cassidy A., 't Mannetje A., Zaridze D., Szeszenia-Dabrowska N., Rudnai P., Lissowska J., Fabianova E., Mates D., Bencko V., Foretova L., Janout V., Brennan P., Boffetta P. Occupational exposure to polycyclic aromatic hydrocarbons and lung cancer risk: a multicenter study in Europe. Occup. Environ. Med. 2010, 67:98-103.
78. Luo J., Hendryx M., Ducatman A. Association between six environmental chemicals and lung cancer incidence in the United States. J. Environ. Publ. Health 2011, 2011:463701.
79. Toyooka S., Mitsudomi T., Soh J., Aokage K., Yamane M., Oto T., Kiura K., Miyoshi S. Molecular oncology of lung cancer. Gen. Thorac. Cardiovasc. Surg. 2011, 59:527-537.
80. Denissenko M.F., Pao A., Tang M.-s., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996, 274:430-432.
81. Feng Z., Hu W., Hu Y., Tang M.-s. Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hortspots and inhibition of DNA repair. Proc. Natl. Acad. Sci. USA 2006, 103:15404-15409.
82. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21:7435-7451.
83. Glick J., Xiong W., Lin Y., Noronha A.M., Wilds C.J., Vouros P. The influence of cytosine methylation on the chemoselectivity of benzo[a]pyrene diol epoxide-oligonucleotide adducts determined using nanoLC/MS/MS. J. Mass. Spectrom. 2009, 44:1241-1248.
84. Guza R., Kotandeniya D., Murphy K., Dissanayake T., Lin C., Giambasu G.M., Lad R.R., Wojciechowski F., Amin S., Sturla S.J., Hudson R.H.E., York D.M., Jankowiak R., Jones R., Tretyakova N.Y. Influence of C-5 substituted cytosine and related nucleoside analogs on the formation of benzo[a]pyrene diol epoxide-dG adducts at CG base pairs of DNA. Nucl. Acids Res. 2011, 39:3988-4006.
85. Tekpli X., Zienolddiny S., Skaug V., Stangeland L., Haugen A., Mollerup S. DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int. J. Cancer 2012, 131:1509-1516.
86. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat. Rev. Cancer 2004, 4:707-717.
87. Rauch T.A., Zhong X., Wu X., Wang M., Kernstine K.H., Wang Z., Riggs A.D., Pfeifer G.P. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc. Natl. Acad. Sci. USA 2008, 105:252-257.
88. Damiani L.A., Yingling C.M., Leng S., Romo P.E., Nakamura J., Belinsky S.A. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res. 2008, 68:9005-9014.
89. W.-b. Liu, L. Ao, Z.-y. Zhou, Z.-h. Cui, Y.-h. Zhou, X.-y. Yuan, Y.-l. Xiang, J. Cao, J.-y. Liu, CpG island hypermethylation of multiple tumor suppressor genes associated with loss of their protein expression during rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine, Biochem. Biophys. Res. Commun. 402 (2010) 507-514.
90. Lin R.-K., Hsieh Y.-S., Lin P., Hsu H.-S., Chen C.-Y., Tang Y.-A., Lee C.-F., Wang Y.-C. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J. Clin. Invest. 2010, 120:521-532.
91. W.-b. Liu, L. Ao, Z.-h. Cui, Z.-y. Zhou, Y.-h. Zhou, X.-y. Yuan, Y.-l. Xiang, J. Cao, J.-y. Liu, Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis, Biochem. Biophys. Res. Commun. 408 (2011) 595-601.
92. W.-b. Liu, Z.-h. Cui, L. Ao, Z.-y. Zhou, Y.-h. Zhou, X.-y. Yuan, Y.-l. Xiang, J.-y. Liu, J. Cao, Aberrant methylation accounts for cell adhesion-related gene silencing during 3-methylcholanthrene and diethylnitrosamine induced multistep rat lung carcinogenesis associated with overexpression of DNA methyltransferases 1 and 3a, Toxicol. Appl. Pharmacol. 251 (2011) 70-78.
93. Daskalos A., Nikolaidis G., Xinarianos G., Savvari P., Cassidy A., Zakopoulou R., Kotsinas A., Gorgoulis V., Field J.K., Liloglou T. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int. J. Cancer 2009, 124:81-87.
94. Saito K., Kawakami K., Matsumoto I., Oda M., Watanabe G., Minamoto T. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin. Cancer Res. 2010, 16:2418-2426.
95. R. Hughes Carvalho, V. Haberle, J. Hou, T. van Gent, S. Thongjuea, W. van IJcken, C. Kockx, R. Brouwer, E. Rijkers, A. Sieuwerts, J. Foekens, M. van Vroonhoven, J. Aerts, F. Grosveld, B. Lenhard, S. Philipsen, Genome-wide DNA methlation profiling of non-small cell lung carcinomas, Epigenet. Chromat. 5 (2012) 9.
96. Valinluck V., Sowers L.C. Inflamation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 2007, 67:5583-5586.
97. Vaissière T., Hung R.J., Zaridze D., Moukeria A., Cuenin C., Fasolo V., Ferro G., Paliwal A., Hainaut P., Brennan P., Tost J., Boffetta P., Herceg Z. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009, 69:243-252.
98. Shen H., Wang L., Spitz M.R., Hong W.K., Mao L., Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002, 62:4992-4995.
99. Vallböhmer D., Brabender J., Yang D., Schneider P.M., Metzger R., Danenberg K.D., Hölscher A.H., Danenberg P.V. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin. Lung Cancer 2006, 8:39-44.
100. van Wezel T., Middeldorp A., Wijnen J.T., Morreau H. A review of the genetic background and tumour profiling in familial colorectal cancer. Mutagenesis 2012, 27:239-245.
101. Watson A.J.M., Collins P.D. Colon cancer: a civilization disorder. Dig. Dis. 2011, 29:222-228.
102. Zheng W., Lee S.-A. Well-done meat intake, heterocyclic amine exposure, and cancer risk. Nutr. Cancer 2009, 61:437-446.
103. Ferguson L.R. Meat and cancer. Meat Sci. 2010, 84:308-313.
104. Tao L., Wang W., Kramer P.M., Lubet R.A., Steele V.E., Pereira M.A. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol. Carcinog. 2004, 39:79-84.
105. Borinstein S.C., Conerly M., Dzieciatkowski S., Biswas S., Washington M.K., Trobridge P., Henikoff S., Grady W.M. Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol. Carcinog. 2010, 49:94-103.
106. Pereira M.A., Tao L., Wang W., Li Y., Umar A., Steele V.E., Lubet R.A. Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-α gene in rat colon tumors. Carcinogenesis 2004, 25:1917-1923.
107. Min/+ mouse model of intestinal cancer. Mol. Carcinog. 2009, 48:920-933.
108. Center M.M., Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol. Biomark. Prev. 2011, 20:2362-2368.
109. Simard E.P., Ward E.M., Siegel R., Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J. Clin. 2012, 62:118-128.
110. Venook A.P., Papandreou C., Furuse J., Ladrón de Guevara L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl. 4):5-13.
111. Yang J.D., Roberts L.R. Epidemiology and management of hepatocellular carcinoma. Infect. Dis. Clin. North Am. 2010, 24:899-919.
112. Nault J.-C., Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin. Liver Dis. 2011, 31:173-187.
113. Nishida N., Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr. Genom. 2011, 12:130-137.
114. Bhave M.R., Wilson M.J., Poirier L.A. C-H-ras and c-K-ras gene hypomethylation in the livers and hepatomas of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis 1988, 9:343-348.
115. INK4A exon 1 in hepatocellular carcinoma. Mol. Carcinog. 2001, 30:138-150.
116. Tsujiuchi T., Sugata E., Masaoka T., Onishi M., Fujii H., Shimizu K., Honoki K. Expression and DNA methylation patterns of Tslc1 and Dal-1 genes in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Cancer Sci. 2007, 98:943-948.
117. Tryndyak V.P., Muskhelishvili L., Kovalchuk O., Rodriguez-Juarez R., Montgomery B., Churchwell M.I., Ross S.A., Beland F.A., Pogribny I.P. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 2006, 27:1713-1720.
118. Bagnyukova T.V., Tryndyak V.P., Montgomery B., Churchwell M.I., Karpf A.R., James S.R., Muskhelishvili L., Beland F.A., Pogribny I.P. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008, 29:638-646.
119. Tao L., Kramer P.M., Ge R., Pereira M.A. Effect of dichloroacetic acid and trichloroacetic acid on DNA methylation in liver and tumors of female B6C3F1 mice. Toxicol. Sci. 1998, 43:139-144.
120. Bachman A.N., Phillips J.M., Goodman J.I. Phenobarbital induces progressive patterns of GC-rich and gene-specific altered DNA methylation in the liver of tumor-prone B6C3F1 mice. Toxicol. Sci. 2006, 91:393-405.
121. Liu J., Waalkes M.P. Liver is a target of arsenic carcinogenesis. Toxicol. Sci. 2008, 105:24-32.
122. Pogribny I.P., Tryndyak V.P., Woods C.G., Witt S.E., Rusyn I. Epigenetic effects of the continuous exposure to peroxisome proliferator WY-14,643 in mouse liver are dependent upon peroxisome proliferator activated receptor α. Mutat. Res. 2007, 625:62-71.
123. Pogribny I.P., Tryndyak V.P., Boureiko A., Melnyk S., Bagnyukova T.V., Montgomery B., Rusyn I. Mechanisms of peroxisome proliferator-induced DNA hypomethylation in rat liver. Mutat. Res. 2008, 644:17-23.
124. Pogribny I.P., Muskhelishvili L., Tryndyak V.P., Beland F.A. The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene. Mutat. Res. 2011, 722:106-113.
125. Ge R., Wang W., Kramer P.M., Yang S., Tao L., Pereira M.A. Wy-14,643-induced hypomethylation of the c-myc gene in mouse liver. Toxicol. Sci. 2001, 62:28-35.
126. Ghoshal K., Li X., Datta J., Bai S., Pogribny I., Pogribny M., Huang Y., Young D., Jacob S.T. A folate- and methyl-deficient diet alters the expression of DNA methyltransferases and methyl CpG binding proteins involved in epigenetic gene silencing in livers of F344 rats. J. Nutr. 2006, 136:1522-1527.
127. Steinmetz K.L., Pogribny I.P., James S.J., Pitot H.C. Hypomethylation of the rat glutathione S-transferase pi (GSTP) promoter region isolated from methyl-deficient livers and GSTP-positive neoplasms. Carcinogenesis 1998, 19:1487-1494.
128. Okabe K., Hayashi M., Yoshida I., Nishimura K., Fukushima N., Tsujiuchi T. Distinct DNA methylation patterns of lysophosphatidic acid receptor genes during rat hepatocarcinogenesis induced by a choline-deficient l-amino acid-defined diet. Arch. Toxicol. 2011, 85:1303-1310.
129. Galbraith D., Gross S.A., Paustenbach D. Benzene and human health: a historical review and appraisal of associations with various diseases. Crit. Rev. Toxicol. 2010, 40:1-46.
130. G. Triebig, Implications of latency period between benzene exposure and development of leukemia - a synopsis of literature, Chem.-Biol. Interact. 184 (2010) 26-29.
131. Vlaanderen J., Lan Q., Kromhout H., Rothman N., Vermeulen R. Occupational benzene exposure and the risk of lymphoma subtypes: a meta-analysis of cohort studies incorporating three study quality dimensions. Environ. Health Perspect. 2011, 119:159-167.
132. McHale C.M., Zhang L., Smith M.T. Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment. Carcinogenesis 2012, 33:240-252.
133. Bollati V., Baccarelli A., Hou L., Bonzini M., Fustinoni S., Cavallo D., Byun H.-M., Jiang J., Marinelli B., Pesatori A.C., Bertazzi P.A., Yang A.S. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 2007, 67:876-880.
134. Gao A., Zuo X., Liu Q., Lu X., Guo W., Tian L. Methylation of PARP-1 promoter involved in the regulation of benzene-induced decrease of PARP-1 mRNA expression. Toxicol. Lett. 2010, 195:114-118.
135. Liu L., Ling X., Liang H., Gao Y., Yang H., Shao J., Tang H. Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone. Toxicol. Lett. 2012, 209:239-245.
136. Carmona F.J., Esteller M. DNA methylation in early neoplasia. Cancer Biomark. 2011, 9:101-111.
137. Piskareva O., Lackington W., Lemass D., Hendrick C., Doolan P., Barron N. The human L1 element: a potential biomarker in cancer prognosis, current status and future directions. Curr. Mol. Med. 2011, 11:286-303.
138. Verbrugge I., Johnstone R.W., Bots M. Promises and challenges of anticancer drugs that target the epigenome. Epigenomics 2011, 3:547-565.
139. J. Marlowe, S.-S. Teo, S.-D. Chibout, F. Pognan, J. Moggs, Mapping the epigenome - impact for toxicology, in: A. Luch (Ed.), Molecular, Clinical and Environmental Toxicology: Molecular Toxicology, vol. 1, Birkhäuser Verlag, Switzerland, 2009, pp. 259-288.
140. LeBaron M.J., Rasoulpour R.J., Klapacz J., Ellis-Hutchings R.G., Hollnagel H.M., Gollapudi B.B. Epigenetics and chemical safety assessment. Mutat. Res. 2010, 705:83-95.
141. R.A. Alyea, N.P. Moore, M.J. LeBaron, B.B. Gollapudi, R.J. Rasoulpour, Is the current product safety assessment paradigm protective for epigenetic mechanisms? J. Pharmacol. Toxicol. Methods, in press.